<DOC>
	<DOCNO>NCT01400698</DOCNO>
	<brief_summary>Study safety SaizenÂ® child bear serious intra-uterine growth retardation ( IUGR ) treat final height . An open , phase III study involve 17 center France . The study enrol child complete 3 2 year treatment least one year post treatment observation Sponsor Studies GF 4001 ( Safety Efficacy Saizen Treatment Young Children Born Severe IUGR ) GF 6283 ( Effect Intermittent versus Continuous Saizen Therapy Young Children Born Severe IUGR ) , respectively . Detailed description : Serious IUGR syndrome characterize low birth length weight gestational age ( le 10 percentile ) . The secretion growth hormone response provocative stimulus ( e.g . arginine , insulin ) normal child . Apart low birth weight , child bear IUGR may minor major malformation . A catch-up period supraphysiological growth velocity generally occur first 6 24 month life 80 90 percent ( % ) child . This generally allow reach normal height . That mean conversely , approximately 10 20 % child maintain statural handicap . Puberty occur normal age retardation bone maturation present first year life disappear quickly . This lead short adult stature subject show spontaneous catch-up first year life . A safe effective mean promote growth without accelerate time tempo puberty would therefore desirable .</brief_summary>
	<brief_title>Saizen Intra-uterine Growth Retardation</brief_title>
	<detailed_description />
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Previous inclusion , good compliance normal completion GF4001 GF6283 treatment growth failure child bear serious IUGR ( 3year continuous rhGH treatment GF4001 2year continuous intermittent rhGH treatment GF6283 ) . Increase height great 0.5 standard deviation ( SD ) first 2 year rhGH treatment GF4001 2 year continuous intermittent rhGH treatment GF6283 . A write Informed Consent begin prestudy visit must obtain parent ( ) /legal guardian ( ) , understanding consent may withdraw subject parent time without prejudice future medical care . Children able understand trial personally sign date write informed consent , . Other protocoldefined inclusion criterion may apply . Known multiple malformation syndrome severe psychomotor retardation and/or body hemihypertrophy . Severe psychomotor retardation . Severe congenital malformation . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Intra-uterine growth retardation ( IUGR )</keyword>
	<keyword>Saizen</keyword>
	<keyword>Recombinant human growth hormone ( r-hGH )</keyword>
	<keyword>Final height</keyword>
	<keyword>Bone age</keyword>
	<keyword>SGA ( Small Gestational Age )</keyword>
</DOC>